Propionibacterium acnes is a Gram-positive anaerobic to aero-tolerant bacterium and part of the skin microbiota in humans. It colonizes areas of skin rich in sebaceous glands, such as the scalp and face. The amount of P. acnes in skin is related to the activity of the sebaceous glands; the population increases after the maturation of sebaceous gland function following puberty.
P. acnes is the major etiological agent of inflammatory acne, and multiple mechanisms are involved in this inflammatory process. P. acnes stimulates the release of interleukin-1 (IL-1), IL-8, and tumor necrosis factor-a (TNF-a) and activates the complement system. This microorganism also produces free fatty acids via the hydrolysis of sebaceous gland triglycerides by its lipase. A wide range of antibiotic classes are effective against acne vulgaris due to P. acnes, such as clindamycin, erythromycin, quinolones, and the tetracycline family. In the last decade, the appearance of antibiotic-resistant P. acnes has increased.
2) A European surveillance study suggested that 15.1% of clinical isolates were resistant to clindamycin and 17.1% to erythromycin. 3) In the 1980s, a double-blind trial of a lotion containing 2% miconazole (MCZ) and 5% benzoyl peroxide was performed in patients with acne vulgaris. 4) High efficacy was seen in 88% of the combination group compared to the group using benzoyl peroxide alone, with a significant reduction in inflammatory lesions. Although MCZ is an imidazole antifungal agent, the compound is also active against Gram-positive bacteria, such as P. acnes, Staphylococcus aureus, and Corynebacterium spp. in vitro.
5) The compound causes the release of cellular K ϩ , which may be related to membrane damage. 6, 7) More than 20 years have passed since the clinical effectiveness of MCZ against acne vulgaris due to P. acnes was first elucidated. Since then, several azole agents have been introduced for the clinical treatment of fungal infections. In this study, we reassessed the in vitro activities of several azole antifungal agents against P. acnes.
MATERIALS AND METHODS
Materials Thirty-two clinical P. acnes isolates were obtained from patients with acne vulgaris. Of them, eight were resistant to both erythromycin [minimum inhibitory concentration (MIC), 8-16 mg/ml] and clindamycin (MIC, 32-64 mg/ml), while all were susceptible to penicillin G (MIC, Ͻ0.25 mg/ml), ampicillin (MIC, Ͻ0.25 mg/ml), piperacillin (MIC, Ͻ8 mg/ml), cefozopran (MIC, Ͻ4 mg/ml), cefmetazole (MIC, Ͻ4 mg/ml), latamoxef (MIC, Ͻ4 mg/ml), imipenem/ cilastatin (MIC, 1 mg/ml), clindamycin (MIC, 0.5 mg/ml), minocycline (MIC, Ͻ1 mg/ml), chloramphenicol (MIC, 4 mg/ml), and tosufloxacin (MIC, Ͻ0.5-1 mg/ml). MCZ, fluconazole (FLZ), itraconazole (ITZ), and voriconazole (VRZ) were purchased from ASTY (Kyokuto Pharmaceutical, Tokyo, Japan); ketoconazole (KTZ) was obtained from Jassen Pharmaceutical (Tokyo, Japan).
Drug Susceptibility Testing The in vitro activities of the five azole agents were determined at concentrations of 0.125-8 mg/ml in reduced Brucella broth (Japan Becton Dickinson, Tokyo, Japan) supplemented with 5 mg/l hemin (Sigma-Aldrich, Tokyo, Japan) and 1 mg/l vitamin K 1 (Sigma-Aldrich) according to the method of Tyrrell et al. 8) The plates were incubated in an anaerobic chamber at 35°C for 48 h. Aliquots of the cultures were taken from each well, diluted serially, and plated onto supplemented Brucella agar plates for counting of the colony-forming units (CFUs).
Time-Kill Assay A time-kill assay was performed using the same reduced Brucella broth as in our drug susceptibility tests. The drug concentrations used were 0, 0.5, 2, and 8 mg/ml. The drugs and strains were added to the tubes in an anaerobic chamber. The final inoculum was approximately 5ϫ10 5 CFUs/ml. Aliquots were removed after 0, 6, 12, 24, and 48 h and plated onto supplemented Brucella agar plates to determine the number of CFUs. Table 1 shows the reduction rate (%) of CFUs for each antibiotic-susceptible and -resistant clinical isolate of P. acnes in agent-containing and -free solutions of MCZ, ITZ, and KTZ. Each agent reduced the number of CFUs of P. acnes in a concentration-dependent manner (0.5-8 mg/ml). At 8 mg/ml, the agents inhibited the growth of the microorganism by more than 80% compared to the control. Of the three compounds, MCZ showed the most potent activity against P. acnes, followed by KTZ and ITZ. This study included eight erythromycin-and clindamycin-resistant clinical isolates. No remarkable difference in drug susceptibility was seen between the antibiotic-susceptible and -resistant isolates. FLZ and VRZ did not reduce the CFUs of any strain at a concentration of 0.5-8 mg/ml. Time-kill assays for each representative antibiotic-susceptible and -resistant strain were carried out using MCZ, KTZ, and ITZ (Fig. 1) . Although the drug concentration used in the assays was generally based on the MIC (e.g., 4-8ϫMIC), the assays were performed using 0, 0.5, 2, and 8 mg/ml each drug since no MIC was determined. The anti-P. acnes activity of all of the drugs was time-dependent and 80% of the microorganisms were eliminated by all of the drugs after 6 h.
In Vitro Activities of Azole Antifungal Agents against Propionibacterium acnes Isolated from Patients with Acne Vulgaris
Azole agents exert their antifungal effects by inhibiting fungal ergosterol biosynthesis. Candida and Aspergillus are major causes of fungal infection. All azole agents are susceptible to Candida, whereas variation in susceptibility to Aspergillus has been reported. Structurally, MCZ and KTZ are "imidazole" agents, whereas ITZ, FLZ, and VRZ are "triazole" agents. Unfortunately, no relationship between the chemical structure and anti-P. acnes activity of these agents has been found. Any evidence of such a relationship may contribute to the development of new anti-P. acnes agents since the appearance of antibiotic-resistant P. acnes is on the rise.
